Actively Recruiting

Phase 3
Age: 6Months +
All Genders
NCT07016750

A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa

Led by Krystal Biotech, Inc. · Updated on 2026-03-12

16

Participants Needed

5

Research Sites

75 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

KB803-EYE-01 is a Phase 3 double-blind, randomized, placebo-controlled, crossover study to evaluate the safety and efficacy of KB803 versus matched placebo in pediatric and adult subjects with recurrent corneal abrasions due to dystrophic epidermolysis bullosa (DEB).

CONDITIONS

Official Title

A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa

Who Can Participate

Age: 6Months +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • The participant or their parent/legal guardian must provide informed consent or assent and be willing to follow study procedures.
  • Participant must be 6 months of age or older at the time of consent.
  • Confirmed diagnosis of dystrophic epidermolysis bullosa (DEB) with a mutation in the COL7A1 gene.
  • Participant must meet minimum corneal abrasion symptom frequency as recorded in the natural history study.
Not Eligible

You will not qualify if you...

  • Starting or changing any new treatment for eye disease during the run-in period, except preservative-free topical antibiotics or artificial tears/lubricants.
  • Use of an investigational agent or off-label ophthalmic product during the run-in period or planned use during the study, unless approved case-by-case.
  • Any condition that could interfere with study assessments, drug administration, or increase risk to the participant as judged by the investigator.
  • Women who are pregnant or nursing.
  • Participants unwilling to comply with contraception requirements.
  • Participants known or expected to be noncompliant with study protocol.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 5 locations

1

Mission Dermatology Center

Rancho Santa Margarita, California, United States, 92688

Actively Recruiting

2

Skin Research Institute

Coral Gables, Florida, United States, 33146

Actively Recruiting

3

UMass Memorial Medical Center

Worcester, Massachusetts, United States, 01605

Actively Recruiting

4

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, United States, 45229

Actively Recruiting

5

Texas Dermatology and Laser Specialists

San Antonio, Texas, United States, 78218

Actively Recruiting

Loading map...

Research Team

D

David Sweet, MD, PhD

CONTACT

B

Brittani Agostini, RN, CCRC

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

CROSSOVER

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa | DecenTrialz